Agenus to Participate in B. Riley Securities' Oncology Investor Conference
January 19 2021 - 12:09PM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an
extensive pipeline of checkpoint antibodies, cell therapies,
adjuvants, and vaccines designed to activate immune response to
cancers and infections, today announced that Dr. Jennifer Buell,
President and COO of Agenus, and Dr. Steven O’Day, CMO of Agenus,
will participate in B. Riley Securities’ Oncology Investor
Conference on January 20-21, 2021.
Agenus Fireside ChatDr. Jennifer BuellThursday,
January 21, 202110:30am – 11:00amThe live webcast can be accessed
via this link:
https://www.webcaster4.com/Webcast/Page/2433/39550
Dr. Jennifer Buell and Dr. Steven O’Day will also participate in
a panel discussion on novel immunotherapies. Please contact your B.
Riley representative for details.
Replays for each event will be available on the Events &
Presentations page of the Agenus website at
https://investor.agenusbio.com/events-and-presentations.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its AgenTus Therapeutics subsidiary), and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For
more information, please visit www.agenusbio.com and our
Twitter handle @agenus_bio. Information that may be important to
investors will be routinely posted on our website and Twitter.
Contact:Agenus Inc.Caroline
Bafundo
212-994-8209Caroline.Bafundo@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024